drugset / Trial / NCT06343077
Intratumoral and Systemic Hiltonol® (Poly-ICLC) in Prostate Cancer Patients on Active Surveillance
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a partially blinded randomized controlled phase II pilot study comparing Poly-ICLC (Hiltonol®) treatment vs no treatment, for prostate cancer participants on active surveillance.
Timeline
- Start
- 2024-01-16
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Hiltonol | Other / unclassified | 1 mg | Intramuscular |
| Comparator | Hiltonol | Other / unclassified | 1.5 mg | Intramuscular |
Indications
No indication recorded.